RCM
ATRA icon

Riverhead Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Riverhead Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10
Closed -$5K – 1500
2019
Q2 		$5K Sell
10
-5
-33% -$3.53K ﹤0.01% 1517
2019
Q1 		$15K Sell
15
-12
-44% -$11.2K ﹤0.01% 1479
2018
Q4 		$23K Sell
27
-56
-67% -$52K ﹤0.01% 1458
2018
Q3 		$86K Sell
83
-38
-31% -$37.2K ﹤0.01% 1425
2018
Q2 		$111K Buy
121
+18
+17% +$19.3K ﹤0.01% 1304
2018
Q1 		$100K Buy
+103
New +$93.9K ﹤0.01% 1330

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverhead Capital Management's ATRA Position: Q3 2019 in Review

Riverhead Capital Management sold out of Atara Biotherapeutics (ATRA) in Q3 2019, closing a stake of 10 shares — an estimated $5K sold.

Riverhead Capital Management first reported a position in ATRA in Q1 2018 and held it in 6 quarters. The position peaked at $111K in Q2 2018. 112 funds tracked by Wall St. Rank hold ATRA as of Q3 2019.

  • Riverhead Capital Management reported no remaining Atara Biotherapeutics position as of Q3 2019 after selling out during the quarter.
  • Riverhead Capital Management sold 10 Atara Biotherapeutics shares in Q3 2019, an estimated $5K.
  • Riverhead Capital Management first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 6 quarters.
  • Riverhead Capital Management's Atara Biotherapeutics position peaked at $111K in Q2 2018.
  • 112 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.